A life-extending prostate cancer drug will continue to only be available to sufferers who have already undergone chemotherapy, the NHS financial watchdog said.
In final draft guidance reassessing the use in the NHS in England of abiraterone, the National Institute for Health and Care Excellence (Nice) ruled that to extend the availability of the drug was "not cost effective at its current price."
There is "clear evidence" that the use of abiraterone before chemotherapy gives patients "longer healthier lives," according to The Institute of Cancer Research, where the drug was discovered.
Nice's chief executive Sir Andrew Dillion said: "We know how important it is for patient to have the option to delay chemotherapy and its associated side affects, so we are disappointed not to be able to recommend abiraterone for use in this way.
"However, the manufacturer's own economic model demonstrated that the drug does not offer enough benefit to justify its price."
More top news
The Prime Minister urged the EU to send a "robust united message" to Moscow over its bombing campaign in Syria.
A man accused of murdering PC Gordon Semple was a Breaking Bad-obsessed sado-masochist who strangled his victim.
Britain is the fourth best country in the world to be a young person, according to a study by the Commonwealth Secretariat.